Evidence map›Paper›PMID 39454719›Full record

ArticleJournal of immunological methods2024

Decreased variability in the site-specific results during participation in the External Quality Assurance Program Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.

Paul M Hargarten, Cassandra G Porth, Mark Berrong, Darin Weed, Miranda Carper, Thomas N Denny, Guido Ferrari, Wes Rountree

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunological methods, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paul M HargartenDuke Research and Discovery at Research Triangle Park, 27 Alexandria Way, Durham, NC, USA.
Cassandra G PorthDuke Research and Discovery at Research Triangle Park, 27 Alexandria Way, Durham, NC, USA.
Mark BerrongDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
Darin WeedDuke Research and Discovery at Research Triangle Park, 27 Alexandria Way, Durham, NC, USA.
Miranda CarperDuke Research and Discovery at Research Triangle Park, 27 Alexandria Way, Durham, NC, USA.
Thomas N DennyDuke Research and Discovery at Research Triangle Park, 27 Alexandria Way, Durham, NC, USA; Department of Medicine, Duke University Medical Center, Durham, NC, USA; Duke Center for AIDS Research, Duke University Medical Center, Durham, NC, USA.
Guido FerrariDuke Center for AIDS Research, Duke University Medical Center, Durham, NC, USA; Duke Global Health Institute, Duke University Medical Center, Durham, NC, USA; Department of Surgery, Center for Human Systems Immunology, and Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
Wes RountreeDuke Research and Discovery at Research Triangle Park, 27 Alexandria Way, Durham, NC, USA. Electronic address: wes.rountree@duke.edu.

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
NIAID NIH HHS HHSN272201000045CNIAID NIH HHS HHSN272201700061CNIAID NIH HHS P30 AI064518
6 · The paper itself

Abstract

The NIAID DAIDS-sponsored External Quality Assurance Program Oversight Laboratory (EQAPOL) manages an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) external proficiency program. The ELISpot program evaluates the accuracy and variability of results across laboratories. The variability in the program is quantified via the dispersion, which is the ratio of the variance over the mean of the background-corrected spot-forming cells (SFC) replicates obtained under stimulation with different peptide pools (CMV, CEF). This report includes the longitudinal analysis of the ELISpot program cohort composed of 22 laboratories from 2011 to 2022 to assess whether the within-lab variability has improved over time. Random intercept models of the dispersion over time showed a significant decrease in overall dispersion from an average of approximately 1.8 in 2011 to approximately 1.25 in 2022. Out of the 21 sites, 16 sites (4 being statistically significant) had a negative trend for dispersion over time. Our finding of a reduction of overall within-lab variability demonstrates the need for and benefit of proficiency testing programs.

Indexed as

Enzyme-Linked Immunospot AssayInterferon-gammaLaboratory Proficiency TestingHumansLaboratoriesLongitudinal StudiesQuality Assurance, Health CareQuality ControlReproducibility of ResultsUnited StatesInterferon-gammaDispersionELISpot assayEQAPOLLongitudinal studyPoissonProficiency testing

Identifiers

PMID39454719
PMCPMC11585408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.